Vitamin D Shows a Sharp Tipping Point for Heart Risk Marker in Type 2 Diabetes

For millions of people living with type 2 diabetes, the greatest long-term threat is not the blood sugar itself but the silent narrowing of arteries that precedes heart attacks and strokes. Clinicians have long searched for simple blood markers that flag this danger early, and one of the most promising is the atherogenic index of plasma, or AIP, a calculated value derived from triglycerides and high-density lipoprotein cholesterol that reflects the balance of atherogenic lipoproteins circulating in the blood. Now a new cross-sectional study from researchers at the People’s Hospital of Gansu Province in Lanzhou, China, published in BMC Endocrine Disorders, suggests that the relationship between this cardiovascular risk marker and vitamin D is anything but a straight line. Instead, the data point to a striking threshold: below roughly 12.3 nanograms per milliliter of serum 25-hydroxyvitamin D, the association between the sunshine hormone and atherogenic risk is strong and inverse, but above that level it essentially vanishes.

The research team, led by Luyan Zhang and colleagues, analyzed medical records from 285 patients with type 2 diabetes who were hospitalized between 2019 and 2021, with a median age of 64 years. Rather than assuming that vitamin D and AIP would relate to each other in a simple linear fashion, the investigators applied a generalized additive model, a flexible statistical framework that allows the shape of a relationship to emerge from the data rather than being forced into a straight line. This approach, combined with smoothing curve fitting, revealed what the authors describe as an L-shaped association: a steep, downward-sloping segment at low vitamin D concentrations followed by a flat plateau at higher concentrations, resembling the letter L when plotted.

To pin down where the curve bends, the team used a threshold-effect model, a technique that searches for the breakpoint at which the slope of the relationship changes significantly. The analysis identified a statistical threshold at 12.3 nanograms per milliliter, with a 95 percent confidence interval spanning 11.3 to 13.7 nanograms per milliliter and a likelihood ratio test yielding a P value of 0.019. Below this exploratory cutoff, every unit change in 25-hydroxyvitamin D was significantly and inversely associated with AIP, with a regression coefficient of minus 0.021 and a P value of 0.0049. Above the threshold, the association flattened completely, with a coefficient of essentially zero and a P value of 0.9635, indicating no detectable relationship whatsoever in that range.

The clinical implications of that breakpoint become clearer when the patients are divided into two groups. Those whose 25-hydroxyvitamin D levels fell below 12.3 nanograms per milliliter did not merely show a different statistical slope; they were measurably sicker on the metabolic parameters that matter. Compared with patients above the threshold, the severely deficient group had significantly elevated hemoglobin A1c, the standard gauge of long-term blood glucose control, with a P value of 0.025, and a higher average atherogenic index of plasma, 0.20 versus 0.13, a difference that reached statistical significance at P equals 0.020. In other words, the patients with the deepest vitamin D deficits carried both poorer glycemic control and a more atherogenic lipid profile.

Importantly, the association did not appear to be an artifact of age or body size. In subgroup analyses stratified by age and body mass index, the inverse correlation between vitamin D and AIP remained consistent, with P values for interaction all exceeding 0.05. That statistical stability across clinical strata strengthens the case that the relationship is not confined to a particular demographic slice of the diabetic population, although the authors are careful to note that subgroup analyses in a single cohort of 285 patients can only be suggestive rather than definitive.

Why might vitamin D and atherogenic lipoproteins be linked at all? The biology offers several plausible threads. Vitamin D receptors are present on vascular smooth muscle cells, immune cells, and pancreatic beta cells, and the active form of the vitamin influences insulin secretion, insulin sensitivity, and inflammatory signaling. Severe deficiency has also been associated with dyslipidemia in prior observational work, potentially through effects on hepatic lipoprotein metabolism. The AIP itself, calculated as the logarithm of the ratio of triglycerides to HDL cholesterol, serves as a surrogate for the burden of small, dense LDL particles, which are particularly prone to penetrating the arterial wall and seeding atherosclerotic plaques. A link between deep vitamin D deficiency and an unfavorable particle profile would therefore fit within a broader picture in which micronutrient status, glucose metabolism, and lipid biology converge on cardiovascular risk.

The L-shaped curve, however, carries a message that goes beyond a simple deficiency warning. If the association between vitamin D and AIP plateaus once levels exceed roughly 12 nanograms per milliliter, then pushing levels ever higher in patients who are already replete may confer no additional benefit with respect to this particular marker. That pattern echoes a recurring theme in nutrition research, where the relationship between a nutrient and a health outcome is often strongest in the deficient range and attenuates or disappears at higher intakes. For a field that has wrestled with disappointing results from large randomized trials of vitamin D supplementation for cardiovascular outcomes, the suggestion that benefit, if any exists, may be concentrated in severely deficient individuals is a potentially important reframing.

The authors themselves are emphatic about the limits of what their study can claim. The 12.3 nanograms per milliliter breakpoint is a data-derived, exploratory value, generated from a single retrospective cohort and not prespecified in advance. The cross-sectional design captures a snapshot in time, which means the direction of causality cannot be established: severe vitamin D deficiency might drive atherogenic lipid changes, or underlying illness, inflammation, and poor metabolic health might simultaneously lower vitamin D levels and worsen AIP. Reverse causation and residual confounding, including factors such as diet, physical activity, kidney function, and medication use, remain possible explanations that a cross-sectional analysis cannot fully exclude. The team explicitly states that the threshold requires external validation in independent populations before any clinical relevance can be established.

Those caveats matter because vitamin D testing and supplementation have become a sprawling, often poorly regulated industry, and headlines about a magic number can easily outpace the evidence. The Endocrine Society and other professional bodies have debated for years where to draw the line between deficiency, insufficiency, and sufficiency, and routine screening of healthy populations remains controversial. A study like this one does not settle those debates, but it does add a nuance that could sharpen them: in patients with type 2 diabetes, the population in whom cardiovascular prevention matters most, the range of vitamin D status over which an association with atherogenic risk appears may be narrow and confined to the severely deficient tail of the distribution.

The study, conducted in accordance with the Declaration of Helsinki and approved by the hospital’s ethics committee with a waiver of individual informed consent for the anonymous analysis of existing records, was supported by the Gansu Provincial People’s Hospital In-hospital Fund Program and the Lanzhou Talent Innovation and Entrepreneurship Project. Its most valuable contribution may be methodological as much as clinical: by modeling non-linearity rather than assuming it away, the researchers surfaced a pattern that conventional linear regression would have averaged into noise or missed entirely. For clinicians managing type 2 diabetes, the practical takeaway for now is measured. Patients with profound vitamin D deficiency, particularly those with poor glycemic control and an unfavorable lipid profile, may warrant attention to their vitamin D status as part of broader cardiovascular risk management. But the promise that correcting a single blood value will meaningfully blunt atherosclerotic risk remains, on this evidence, a hypothesis awaiting the rigorous testing that only longitudinal and interventional studies can provide.

Subject of Research: The non-linear association between serum 25-hydroxyvitamin D and the atherogenic index of plasma in patients with type 2 diabetes

Article Title: Non-linear association and threshold effect of serum 25-hydroxyvitamin D on atherogenic index of plasma in patients with type 2 diabetes

Article References: Zhang, L., Hu, A., Li, Y., Wang, Y., & shi, Y. (2026). Non-linear association and threshold effect of serum 25-hydroxyvitamin D on atherogenic index of plasma in patients with type 2 diabetes. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02623-1

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02623-1

Keywords: vitamin D, 25-hydroxyvitamin D, atherogenic index of plasma, type 2 diabetes, cardiovascular risk, threshold effect, non-linear association, dyslipidemia, HbA1c, cross-sectional study, generalized additive model, endocrinology